Hemispherx Biopharma (HEB) 1.24 $HEB Hemispherx
Post# of 273332
Posted On: 09/25/2016 1:13:46 PM
Hemispherx Biopharma (HEB) 1.24 $HEB
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case
GlobeNewswire - Thu Sep 22, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company"
, announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and class action case captioned Kastis, et al. v. Carter, et al.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards
GlobeNewswire - Mon Sep 19, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company" , announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with the NYSE MKT's continued listing standards set forth in Part 10 of the NYSE MKT Company Guide.
HEB: 1.24 (-0.07)
Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company" , announced today that that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City.
HEB: 1.24 (-0.07)
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
GlobeNewswire - Mon Aug 29, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced that it will present at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA. Dr. Christopher Nicodemus of Hemispherx' Scientific Advisory Board will present the presentation entitled "RINTATOLIMOD: Enhancement of immune responses with a well-tolerated selective TLR3 agonist. The potential for I-O combination."
HEB: 1.24 (-0.07)
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.71 (-0.05), ALNY: 75.57 (-1.52), HEB: 1.24 (-0.07), VBLT: 4.85 (-0.01)
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise
GlobeNewswire - Fri Aug 19, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its member's scientific and pharmaceutical expertise and advice to advance the Company's drug development programs by providing guidance on steering the company forward and capitalizing on business opportunities as well as interactions with the Food and Drug Administration. The Board consists of William Mitchell, M.D., Ph.D., Ronald Brus, M.D., W. Neal Burnette, Ph.D., and Christopher Nicodemus, M.D., F.A.C.P.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript
GlobeNewswire - Mon Aug 15, 12:30PM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" has posted the transcript of The Wall Street Transcript interview with Thomas Equels and William Mitchell, PhD, MD. The transcript can be viewed on the company's website at http://ir.hemispherx.net/Events_Presentations.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company
GlobeNewswire - Wed Jun 08, 10:53AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) is pleased to announce that it has entered into multiple agreements and stipulations to settle all material litigation. "All four derivative cases, described in detail in prior public filings, have now been settled, subject to final Court approval. Two pending disputes in mediation with Company insurers have also been settled with a commitment to pay $3,500,000 to the Company," declared Thomas K. Equels, CEO of Hemispherx.
HEB: 1.24 (-0.07)
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
GlobeNewswire - Tue Jun 07, 7:30AM CDT
Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology, Microbiology and Immunology at Vanderbilt University, recently published an article entitled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)," in Expert Review of Clinical Pharmacology, 2016 Jun;9(6):755-70. doi:10.1586/17512433.2016.1172960.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights (IP) of William A. Carter, M.D., the former CEO of Hemispherx. Further, all IP that is related to Ampligen(R) and Alferon(R) and that was created by Carter prior to and during his employment at Hemispherx has now been fully and irrevocably assigned to Hemispherx. The Company believes the omnibus assignment adds assurance of no future intellectual property claim from Carter. Additionally, the Company hopes this omnibus assignment will serve to dispose of investor and potential co-development partner questions on this particular issue.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm
GlobeNewswire - Tue May 31, 7:30AM CDT
Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latino America (GP Pharm), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com). The previous agreement had expired on June 14, 2015. Under this new agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen(R), an experimental therapeutic, to treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and for commercializing Ampligen(R) for this indication in Argentina. The Company has granted GP Pharm expanded rights to sell this experimental therapeutic into other Latin American countries based upon GP Pharm achieving certain performance milestones. The Company has also granted GP Pharm an option to market Alferon N Injection(R) trademarked in Argentina as Naturaferon(R), its FDA approved natural interferon, in Argentina and other Latin America countries. In 2012, under GP's original agreement they were able to extend Alferon's indication in Argentina to treat any disease that is refractory to Recombinant Interferon. Under this Agreement, the Company will manufacture and supply Ampligen(R) and Alferon(R) to GP Pharm.
HEB: 1.24 (-0.07)
UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
GlobeNewswire - Tue May 24, 11:25AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
HEB: 1.24 (-0.07)
Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
GlobeNewswire - Mon May 23, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016
GlobeNewswire - Thu May 12, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" announced today that it anticipates filing its 2016 first quarter financial results for quarter ended March 31 on Monday, May 16, 2016. Hemispherx will host a conference call at 1:00 p.m. Eastern Daylight Time (EDT) on Tuesday, May 17, 2016 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the call.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon(R) and Ampligen(R)
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company" or "Hemispherx" announced that it has signed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the life sciences market, to advance the company's strategic plan to capitalize on business opportunities in the United States and in target countries around the world.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon(R) N Clinical Trial on Closely Related Flavivirus (West Nile)
GlobeNewswire - Tue Feb 09, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and potential uses of its natural alpha interferon (Alferon(R) N and Alferon(R) LDO) and rintatolimod (Ampligen(R)) drug formulations against the Zika virus. The recent orphan drug designations of Ampligen(R) for Ebola and Alferon(R) N for MERS viruses by the European Regulatory authorities demonstrates the global need for drugs that possess broad antiviral activities against emerging viruses.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value
GlobeNewswire - Wed Feb 03, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today, February 3, 2016, a Voluntary Pay for Stock Plan (the "Plan" . Hemispherx Biopharma is seeking to create ownership incentives as well as to provide additional cash for various operational activities. All members of Senior Management, all members of the Board of Directors, and all employees volunteered to participate. Senior Management believes that this Plan creates significant shareholder value as the participants will voluntarily use up to 20% of their salaries to purchase stock from the Company, creating long term incentives for them to reach corporate goals. In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. The plan goes into effect immediately. "We are all excited for the opportunity to invest in Hemispherx's future," said Hemispherx's Chairman and CEO, Dr. William A. Carter, "Our efforts will be redoubled in 2016 to make progress on all of our major goals."
HEB: 1.24 (-0.07)
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
GlobeNewswire - Mon Oct 19, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" announces that the European subsidiary, "Hemispherx Biopharma Europe N.V./S.A." gained a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Alferon N Injection(R) to treat Middle East Respiratory Syndrome (MERS).
HEB: 1.24 (-0.07)
New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma
GlobeNewswire - Wed Sep 30, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announces that Arrowhead BID issued an analyst report on September 29, 2015, which can be seen at www.abid.co at the following link.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
GlobeNewswire - Mon Sep 28, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced that it received formal notice on September 21, 2015, that the European Patent Office's Examining Division granted the Company's application titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" by inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3 (TLR3), thereby conveying an important range of therapeutic opportunities. This form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA which can inhibit receptor binding. Pharmaceutical formulations containing this nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the granted patent.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case
GlobeNewswire - Thu Sep 22, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company"
, announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and class action case captioned Kastis, et al. v. Carter, et al. HEB: 1.24 (-0.07)
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards
GlobeNewswire - Mon Sep 19, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company"
, announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with the NYSE MKT's continued listing standards set forth in Part 10 of the NYSE MKT Company Guide. HEB: 1.24 (-0.07)
Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company"
, announced today that that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City. HEB: 1.24 (-0.07)
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
GlobeNewswire - Mon Aug 29, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced that it will present at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA. Dr. Christopher Nicodemus of Hemispherx' Scientific Advisory Board will present the presentation entitled "RINTATOLIMOD: Enhancement of immune responses with a well-tolerated selective TLR3 agonist. The potential for I-O combination." HEB: 1.24 (-0.07)
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.71 (-0.05), ALNY: 75.57 (-1.52), HEB: 1.24 (-0.07), VBLT: 4.85 (-0.01)
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise
GlobeNewswire - Fri Aug 19, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its member's scientific and pharmaceutical expertise and advice to advance the Company's drug development programs by providing guidance on steering the company forward and capitalizing on business opportunities as well as interactions with the Food and Drug Administration. The Board consists of William Mitchell, M.D., Ph.D., Ronald Brus, M.D., W. Neal Burnette, Ph.D., and Christopher Nicodemus, M.D., F.A.C.P.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript
GlobeNewswire - Mon Aug 15, 12:30PM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
has posted the transcript of The Wall Street Transcript interview with Thomas Equels and William Mitchell, PhD, MD. The transcript can be viewed on the company's website at http://ir.hemispherx.net/Events_Presentations. HEB: 1.24 (-0.07)
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company
GlobeNewswire - Wed Jun 08, 10:53AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) is pleased to announce that it has entered into multiple agreements and stipulations to settle all material litigation. "All four derivative cases, described in detail in prior public filings, have now been settled, subject to final Court approval. Two pending disputes in mediation with Company insurers have also been settled with a commitment to pay $3,500,000 to the Company," declared Thomas K. Equels, CEO of Hemispherx.
HEB: 1.24 (-0.07)
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
GlobeNewswire - Tue Jun 07, 7:30AM CDT
Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology, Microbiology and Immunology at Vanderbilt University, recently published an article entitled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)," in Expert Review of Clinical Pharmacology, 2016 Jun;9(6):755-70. doi:10.1586/17512433.2016.1172960.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights (IP) of William A. Carter, M.D., the former CEO of Hemispherx. Further, all IP that is related to Ampligen(R) and Alferon(R) and that was created by Carter prior to and during his employment at Hemispherx has now been fully and irrevocably assigned to Hemispherx. The Company believes the omnibus assignment adds assurance of no future intellectual property claim from Carter. Additionally, the Company hopes this omnibus assignment will serve to dispose of investor and potential co-development partner questions on this particular issue.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm
GlobeNewswire - Tue May 31, 7:30AM CDT
Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latino America (GP Pharm), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com). The previous agreement had expired on June 14, 2015. Under this new agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen(R), an experimental therapeutic, to treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and for commercializing Ampligen(R) for this indication in Argentina. The Company has granted GP Pharm expanded rights to sell this experimental therapeutic into other Latin American countries based upon GP Pharm achieving certain performance milestones. The Company has also granted GP Pharm an option to market Alferon N Injection(R) trademarked in Argentina as Naturaferon(R), its FDA approved natural interferon, in Argentina and other Latin America countries. In 2012, under GP's original agreement they were able to extend Alferon's indication in Argentina to treat any disease that is refractory to Recombinant Interferon. Under this Agreement, the Company will manufacture and supply Ampligen(R) and Alferon(R) to GP Pharm.
HEB: 1.24 (-0.07)
UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
GlobeNewswire - Tue May 24, 11:25AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
HEB: 1.24 (-0.07)
Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
GlobeNewswire - Mon May 23, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016
GlobeNewswire - Thu May 12, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
announced today that it anticipates filing its 2016 first quarter financial results for quarter ended March 31 on Monday, May 16, 2016. Hemispherx will host a conference call at 1:00 p.m. Eastern Daylight Time (EDT) on Tuesday, May 17, 2016 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the call. HEB: 1.24 (-0.07)
Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon(R) and Ampligen(R)
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) (the "Company" or "Hemispherx"
announced that it has signed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the life sciences market, to advance the company's strategic plan to capitalize on business opportunities in the United States and in target countries around the world. HEB: 1.24 (-0.07)
Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon(R) N Clinical Trial on Closely Related Flavivirus (West Nile)
GlobeNewswire - Tue Feb 09, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and potential uses of its natural alpha interferon (Alferon(R) N and Alferon(R) LDO) and rintatolimod (Ampligen(R)) drug formulations against the Zika virus. The recent orphan drug designations of Ampligen(R) for Ebola and Alferon(R) N for MERS viruses by the European Regulatory authorities demonstrates the global need for drugs that possess broad antiviral activities against emerging viruses.
HEB: 1.24 (-0.07)
Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value
GlobeNewswire - Wed Feb 03, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today, February 3, 2016, a Voluntary Pay for Stock Plan (the "Plan"
. Hemispherx Biopharma is seeking to create ownership incentives as well as to provide additional cash for various operational activities. All members of Senior Management, all members of the Board of Directors, and all employees volunteered to participate. Senior Management believes that this Plan creates significant shareholder value as the participants will voluntarily use up to 20% of their salaries to purchase stock from the Company, creating long term incentives for them to reach corporate goals. In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. The plan goes into effect immediately. "We are all excited for the opportunity to invest in Hemispherx's future," said Hemispherx's Chairman and CEO, Dr. William A. Carter, "Our efforts will be redoubled in 2016 to make progress on all of our major goals." HEB: 1.24 (-0.07)
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
GlobeNewswire - Mon Oct 19, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
announces that the European subsidiary, "Hemispherx Biopharma Europe N.V./S.A." gained a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Alferon N Injection(R) to treat Middle East Respiratory Syndrome (MERS). HEB: 1.24 (-0.07)
New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma
GlobeNewswire - Wed Sep 30, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announces that Arrowhead BID issued an analyst report on September 29, 2015, which can be seen at www.abid.co at the following link. HEB: 1.24 (-0.07)
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
GlobeNewswire - Mon Sep 28, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced that it received formal notice on September 21, 2015, that the European Patent Office's Examining Division granted the Company's application titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" by inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3 (TLR3), thereby conveying an important range of therapeutic opportunities. This form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA which can inhibit receptor binding. Pharmaceutical formulations containing this nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the granted patent. HEB: 1.24 (-0.07)
(0)
(0)